Objective: This study was undertaken to report clinical presentations and outcomes of CASPR2-IgG-associated seizures.
Methods: Mayo Clinic Neuroimmunology database was queried to identify CASPR2-IgG-seropositive (CASPR2-IgG+) patients evaluated at our institution (2009-2019).
Results: Of the 53 CASPR2-IgG+ patients (titer ≥ 1:10), 20 had seizures (38%).